Neuright, Inc., is a biotech start-up and academic spin-out company from the University of Maine. Our name comes straight from our company’s goal, which is to “Make Neuropathy Right, in All Its Forms.” Because peripheral neuropathy (especially aging and diabetes small fiber neuropathy) is a progressive disease that can be treated better the earlier it’s diagnosed, our methodology is captured in our tagline: Catch it early, fix it fast.
Business Model At Neuright, Inc. our business model is to offer a diagnostic platform at a reasonable price that will be able to accept modifications to deliver drugs and therapies as they become available. The device will establish trust and confidence with caregivers and patients at the diagnostic stage, allowing all stakeholders to make the most of the treatment stage.
Neuright’s Mission Provide superior quality diagnostics for the early detection of neuropathy through innovative biomedical device design and rigorous pre-clinical and clinical testing, while striving to develop novel treatment and therapeutic options in a patient-centric manner.
Neuright’s Vision Neuright envisions a world free from peripheral neuropathy in all its forms by providing better clinical outcomes for the millions suffering from this debilitating condition without compromising scientific rigor and integrity for profit.
Neuright’s Promise Our promise is ethical and transparent research, peer-validated science and technology; to be backed by independent third-party certification.
The device is currently PATENT PENDING and is covered by a Provisional Patent submitted May 8, 2020 (US Application No. 63\022,258).
